The release of the Osteoporosis Canada 2023 Clinical Practice Guideline will support Canadian healthcare providers in providing the most current evidence-based information for patient centred care to optimise skeletal health […]

Menopause is associated with a range of symptoms which may affect quality of life as well may increase an individual’s risk of chronic conditions such as osteoporosis or cardiovascular disease.  […]

Dr. Rowena Ridout is the new chair of Osteoporosis Canada’s Scientific Advisory Council. Rowena has been involved with Osteoporosis Canada since 2010 as an active member of the Scientific Advisory Council.  […]

Jack Hirsh Award Rick Adachi MD, FRCPC The McMaster Academic and Education Department of Medicine Awards review committee have selected an outstanding group of individuals for the 2020-2021 academic year. […]

Available Volunteer Opportunities Call for Nominations – Board of Directors After evaluating the strengths of the existing Board of Directors, the Board Development Committee is seeking individuals with the following […]

SAC Newsletter SAC Link The SAC Link is a quarterly newsletter for members of Osteoporosis Canada’s Scientific Advisory Council. It includes Osteoporosis Canada news, updates from committees and member news. […]

Dr. Mohit Bhandari, a member of the SAC Executive committee,  a Professor in the Department of Surgery at McMaster University and a leader in the field of orthopedic surgery has […]

We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]

We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]